|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
Early Drug Target Validation | ||||||||||||||||
April 02, 2001 | ||||||||||||||||
Vision in Business, Forum Park Hotel, Geneva, Switzerland 21/05/01-22/05/01 -Pfizer perspective: Methods to select the best targets to validate -How GlaxoSmithkline use transgenic knockouts for evidence based target selection and validation -Using in-vivo mammalian data to speed your target validation process -Using differential gene expression analysis to identify potential targets -Antisense and functional genomics: real working examples in tissue culture and in-vivo |
||||||||||||||||
Organized by: | Vision in Business | |||||||||||||||
Invited Speakers: | Deltagen Cambridge Drug Discovery Serono GlaxoSmithKline Pharmagene AstraZeneca Pharmagene PLC Pfizer |
|||||||||||||||
Deadline for Abstracts: | 22/05/01 | |||||||||||||||
Registration: | 21/05/01 0845 Registration and coffee | |||||||||||||||
E-mail: | postmaster2@visioninbusiness.com | |||||||||||||||
Posted by: | Emma Baker | |||||||||||||||
Host: | mail.visioninbusiness.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |